Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial
Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial have?
Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial has 65 citations in the OpenAlex counts ScholarIQ stores.
When was Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial published?
Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial has 2023 year in the ScholarIQ index.
What is the open-access status of Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial?
Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial has hybrid oa status in the ScholarIQ index.
What is the DOI of Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial?
The DOI for Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial is on the source record.
What is the PMID of Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial?
The PMID for Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial is on the source record.
What is the OpenAlex record for Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial?
The OpenAlex for Efficacy and Safety of the <scp>TYK2</scp>/<scp>JAK1</scp> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <scp>IIb</scp> Randomized Controlled Trial is on the source record.